{"pmid":32361326,"title":"Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.","text":["Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.","J Clin Virol","Fleming, Andrew B","Raabe, Vanessa","32361326"],"journal":"J Clin Virol","authors":["Fleming, Andrew B","Raabe, Vanessa"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361326","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jcv.2020.104388","topics":["Treatment"],"weight":1,"_version_":1666138495550226432,"score":9.490897,"similar":[{"pmid":32298458,"title":"Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?","text":["Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?","Swiss Med Wkly","Negro, Francesco","32298458"],"journal":"Swiss Med Wkly","authors":["Negro, Francesco"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298458","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.4414/smw.2020.20249","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493258039298,"score":55.623425},{"pmid":32504046,"title":"Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.","text":["Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.","Nat Biotechnol","Eroshenko, Nikolai","Gill, Taylor","Keaveney, Marianna K","Church, George M","Trevejo, Jose M","Rajaniemi, Hannu","32504046"],"journal":"Nat Biotechnol","authors":["Eroshenko, Nikolai","Gill, Taylor","Keaveney, Marianna K","Church, George M","Trevejo, Jose M","Rajaniemi, Hannu"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504046","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1038/s41587-020-0577-1","topics":["Mechanism","Treatment"],"weight":1,"_version_":1668892488326184960,"score":53.171497},{"pmid":32428113,"title":"Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding, and Antibody-dependent Enhancement (ADE).","text":["Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding, and Antibody-dependent Enhancement (ADE).","The world is currently facing a serious SARS-CoV-2 infection pandemic. </mac_aq>This virus is a new isolate of coronavirus, and the current infection crisis has surpassed the SARS and MERS epidemics</mac_aq> that occurred in 2002 and 2013, respectively. SARS-CoV-2 has currently infected more than 142,000 people, causing </mac_aq>5,000 deaths and spreading across more than 130 </mac_aq>countries worldwide. The spreading capacity of the virus clearly demonstrates the potential threat </mac_aq>of respiratory viruses to human health, thereby reiterating to the governments around the world that preventive </mac_aq>health policies and scientific research are pivotal to overcoming the crisis. Coronavirus disease (COVID-19) causes flu-like symptoms in most cases. However, approximately 15% of the patients need hospitalization, and 5% require assisted ventilation, depending on the cohorts studied. What is intriguing, however, is the higher susceptibility of the elderly, especially individuals who are older than 60 years of age, and have comorbidities, including hypertension, diabetes, and heart disease. In fact, the death rate in this group may be up to 10-12%. Interestingly, children are somehow less susceptible and are not considered as a risk group. Therefore, in this review, we discuss some possible molecular and cellular mechanisms by virtue of which the elderly subjects may be more susceptible to severe COVID-19. Toward this, we raise two main </mac_aq>points, i) increased ACE-2 expression in pulmonary and heart tissues in users of chronic angiotensin 1 </mac_aq>receptor (AT1R) blockers; and ii) antibody-dependent enhancement (ADE) after previous exposure to other circulating coronaviruses. We believe that these points are pivotal for a better understanding of the pathogenesis of severe COVID-19, and must be carefully addressed by physicians and scientists in the field.","Clinics (Sao Paulo)","Peron, Jean Pierre Schatzmann","Nakaya, Helder","32428113"],"abstract":["The world is currently facing a serious SARS-CoV-2 infection pandemic. </mac_aq>This virus is a new isolate of coronavirus, and the current infection crisis has surpassed the SARS and MERS epidemics</mac_aq> that occurred in 2002 and 2013, respectively. SARS-CoV-2 has currently infected more than 142,000 people, causing </mac_aq>5,000 deaths and spreading across more than 130 </mac_aq>countries worldwide. The spreading capacity of the virus clearly demonstrates the potential threat </mac_aq>of respiratory viruses to human health, thereby reiterating to the governments around the world that preventive </mac_aq>health policies and scientific research are pivotal to overcoming the crisis. Coronavirus disease (COVID-19) causes flu-like symptoms in most cases. However, approximately 15% of the patients need hospitalization, and 5% require assisted ventilation, depending on the cohorts studied. What is intriguing, however, is the higher susceptibility of the elderly, especially individuals who are older than 60 years of age, and have comorbidities, including hypertension, diabetes, and heart disease. In fact, the death rate in this group may be up to 10-12%. Interestingly, children are somehow less susceptible and are not considered as a risk group. Therefore, in this review, we discuss some possible molecular and cellular mechanisms by virtue of which the elderly subjects may be more susceptible to severe COVID-19. Toward this, we raise two main </mac_aq>points, i) increased ACE-2 expression in pulmonary and heart tissues in users of chronic angiotensin 1 </mac_aq>receptor (AT1R) blockers; and ii) antibody-dependent enhancement (ADE) after previous exposure to other circulating coronaviruses. We believe that these points are pivotal for a better understanding of the pathogenesis of severe COVID-19, and must be carefully addressed by physicians and scientists in the field."],"journal":"Clinics (Sao Paulo)","authors":["Peron, Jean Pierre Schatzmann","Nakaya, Helder"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428113","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.6061/clinics/2020/e1912","locations":["Shedding"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728866652160,"score":45.372288},{"pmid":32305026,"pmcid":"PMC7146649","title":"Challenges of Convalescent Plasma Therapy on COVID-19.","text":["Challenges of Convalescent Plasma Therapy on COVID-19.","J Clin Virol","Zhao, Qian","He, Yong","32305026"],"journal":"J Clin Virol","authors":["Zhao, Qian","He, Yong"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32305026","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jcv.2020.104358","topics":["Treatment"],"weight":1,"_version_":1666138491066515456,"score":45.047516},{"pmid":32113510,"pmcid":"PMC7128218","title":"Convalescent plasma as a potential therapy for COVID-19.","text":["Convalescent plasma as a potential therapy for COVID-19.","Lancet Infect Dis","Chen, Long","Xiong, Jing","Bao, Lei","Shi, Yuan","32113510"],"journal":"Lancet Infect Dis","authors":["Chen, Long","Xiong, Jing","Bao, Lei","Shi, Yuan"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32113510","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1016/S1473-3099(20)30141-9","link_comment_for":"25030060","topics":["Treatment"],"weight":1,"_version_":1666138492844900353,"score":45.047516}]}